These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31459613)

  • 1. Examining the Impact of Antimicrobial Fluoroquinolones on Human DNA Topoisomerase IIα and IIβ.
    Fief CA; Hoang KG; Phipps SD; Wallace JL; Deweese JE
    ACS Omega; 2019 Feb; 4(2):4049-4055. PubMed ID: 31459613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage.
    Bromberg KD; Burgin AB; Osheroff N
    Biochemistry; 2003 Apr; 42(12):3393-8. PubMed ID: 12653542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
    Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
    Biochemistry; 2000 Mar; 39(10):2726-32. PubMed ID: 10704224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones.
    Morrissey I; George JT
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():101-6. PubMed ID: 10824040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
    Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
    Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mode of action of fluoroquinolones.
    Hooper DC
    Drugs; 1999; 58 Suppl 2():6-10. PubMed ID: 10553698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.
    Hammonds TR; Foster SR; Maxwell A
    J Mol Biol; 2000 Jul; 300(3):481-91. PubMed ID: 10884345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde.
    Anderson VE; Osheroff N
    Curr Pharm Des; 2001 Mar; 7(5):337-53. PubMed ID: 11254893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
    Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
    Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sitafloxacin: antimicrobial activity against ciprofloxacin-selected laboratory mutants of Mycoplasma genitalium and inhibitory activity against its DNA gyrase and topoisomerase IV.
    Deguchi T; Kikuchi M; Yasuda M; Ito S
    J Infect Chemother; 2015 Jan; 21(1):74-5. PubMed ID: 25245990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
    Strahilevitz J; Hooper DC
    Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.
    Blanche F; Cameron B; Bernard FX; Maton L; Manse B; Ferrero L; Ratet N; Lecoq C; Goniot A; Bisch D; Crouzet J
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2714-20. PubMed ID: 9124828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.
    Zhao X; Xu C; Domagala J; Drlica K
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13991-6. PubMed ID: 9391140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity.
    Naeem A; Badshah SL; Muska M; Ahmad N; Khan K
    Molecules; 2016 Mar; 21(4):268. PubMed ID: 27043501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation.
    Perrone CE; Takahashi KC; Williams GM
    Toxicol Sci; 2002 Sep; 69(1):16-22. PubMed ID: 12215656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basis for the discrimination of supercoil handedness during DNA cleavage by human and bacterial type II topoisomerases.
    Jian JY; McCarty KD; Byl JAW; Guengerich FP; Neuman KC; Osheroff N
    Nucleic Acids Res; 2023 May; 51(8):3888-3902. PubMed ID: 36999602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluoroquinolones: is there a different mechanism of action and resistance against Streptococcus pneumoniae?
    Harding I; Simpson I
    J Chemother; 2000 Oct; 12 Suppl 4():7-15. PubMed ID: 11131958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A high-throughput fluorescence anisotropy-based assay for human topoisomerase II β-catalyzed ATP-dependent supercoiled DNA relaxation.
    Shapiro AB; Austin CA
    Anal Biochem; 2014 Mar; 448():23-9. PubMed ID: 24309019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.